Soleno Therapeutics
Market Cap
US$99.7m
Last Updated
2020/03/31 03:43 UTC
Data Sources
Company Financials +
Executive Summary
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Soleno Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SLNO's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
9.9%
SLNO
4.7%
US Biotechs
7.2%
US Market
1 Year Return
12.6%
SLNO
1.8%
US Biotechs
-10.4%
US Market
Return vs Industry: SLNO exceeded the US Biotechs industry which returned -0.7% over the past year.
Return vs Market: SLNO exceeded the US Market which returned -12.7% over the past year.
Shareholder returns
| SLNO | Industry | Market | |
|---|---|---|---|
| 7 Day | 9.9% | 4.7% | 7.2% |
| 30 Day | -19.8% | -3.5% | -12.6% |
| 90 Day | -24.2% | -5.4% | -19.4% |
| 1 Year | 12.6%12.6% | 2.6%1.8% | -8.5%-10.4% |
| 3 Year | -32.4%-32.4% | 14.0%11.1% | 15.8%8.3% |
| 5 Year | -93.9%-93.9% | -3.6%-7.9% | 35.8%21.0% |
Price Volatility Vs. Market
How volatile is Soleno Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall St
What Kind Of Shareholder Owns Most Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock?5 months ago | Simply Wall St
Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?6 months ago | Simply Wall St
What Kind Of Investor Owns Most Of Soleno Therapeutics, Inc. (NASDAQ:SLNO)?Valuation
Is Soleno Therapeutics undervalued compared to its fair value and its price relative to the market?
6.66x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SLNO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SLNO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SLNO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SLNO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SLNO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SLNO is overvalued based on its PB Ratio (6.8x) compared to the US Biotechs industry average (2.5x).
Next Steps
Future Growth
How is Soleno Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
9.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLNO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLNO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLNO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if SLNO's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if SLNO's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SLNO's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Soleno Therapeutics performed over the past 5 years?
-5.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SLNO is currently unprofitable.
Growing Profit Margin: SLNO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SLNO is unprofitable, and losses have increased over the past 5 years at a rate of -5.9% per year.
Accelerating Growth: Unable to compare SLNO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLNO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: SLNO has a negative Return on Equity (-205.89%), as it is currently unprofitable.
Next Steps
Financial Health
How is Soleno Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SLNO's short term assets ($21.1M) exceed its short term liabilities ($5.0M).
Long Term Liabilities: SLNO's short term assets ($21.1M) exceed its long term liabilities ($18.3M).
Debt to Equity History and Analysis
Debt Level: SLNO is debt free.
Reducing Debt: SLNO currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Inventory Level: SLNO has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if SLNO's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLNO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SLNO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Soleno Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SLNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SLNO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SLNO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SLNO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SLNO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.4yrs
Average management tenure
CEO
Anish Bhatnagar (49yo)
no data
Tenure
US$951,911
Compensation
Dr. Anish Bhatnagar, M.D. serves as President and Chief Executive Officer of Soleno Therapeutics, Inc. Dr. Bhatnagar served as the Chief Executive Officer of Soleno Therapeutics, Inc. since February 6, 201 ...
CEO Compensation Analysis
Compensation vs Market: Anish's total compensation ($USD951.91K) is above average for companies of similar size in the US market ($USD605.16K).
Compensation vs Earnings: Anish's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$951.91k | 0.14% $144.0k | |
| CFO, Principal Financial & Accounting Officer | 0.25yr | no data | 0.022% $22.3k | |
| Senior VP & GM | 5.17yrs | US$270.00k | no data | |
| Senior Vice President of Drug Development | no data | no data | no data | |
| Head of Regulatory Affairs and Quality | no data | no data | no data | |
| Consultant | 2.42yrs | US$358.00k | no data |
2.4yrs
Average Tenure
56yo
Average Age
Experienced Management: SLNO's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$951.91k | 0.14% $144.0k | |
| Independent Chairman | 6yrs | US$83.83k | 1.09% $1.1m | |
| Independent Director | 5.67yrs | US$75.94k | 0.056% $55.3k | |
| Independent Director | 3yrs | US$60.91k | 0.036% $35.4k | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 1.25yrs | US$20.23k | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data |
5.7yrs
Average Tenure
59yo
Average Age
Experienced Board: SLNO's board of directors are considered experienced (5.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 62.8%.
Top Shareholders
Company Information
Soleno Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Soleno Therapeutics, Inc.
- Ticker: SLNO
- Exchange: NasdaqCM
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$99.652m
- Shares outstanding: 44.69m
- Website: https://www.soleno.life
Number of Employees
Location
- Soleno Therapeutics, Inc.
- 1235 Radio Road
- Suite 110
- Redwood City
- California
- 94065
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SLNO | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Nov 2014 |
| 6XC1 | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Nov 2014 |
| 6XC1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 2014 |
Biography
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. It has collaboration agreement with Casimir Inc. to develop DCCR tablets for patients with PWS. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/03/31 03:43 |
| End of Day Share Price | 2020/03/30 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.